Eduardo Castañón Álvarez

Dr. Eduardo Castañón Álvarez


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2019 in Drug Safety
Verified
Journal Article
Closed access
IBIosune Baraibar
Iosune Baraibar
IMIGNACIO MELERO
IGNACIO MELERO
MPMariano Ponz-Sarvisé
Mariano Ponz-Sarvisé
EÁEduardo Castañón Álvarez
Eduardo Castañón Álvarez

11 January 2013 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
EÁEduardo Castañón Álvarez
Eduardo Castañón Álvarez
Joaquim Bosch BarreraJoaquim Bosch Barrera
Joaquim Bosch Barrera
ILInés López
Inés López
VCVíctor Collado
Víctor Collado
MMMarta Moreno-Jiménez
Marta Moreno-Jiménez
IGIgnacio Gil-Bazo
Ignacio Gil-Bazo
Background: Inhibitor of DNA binding 1 (Id1) and 3 (Id3) genes have been related with the inhibition of cell differentiation, cell growth promotion and tumor metastasis. Recently, Id1 has been identified as an independent prognostic factor in patients with lung adenocarcinoma, regardless of the stage. Furthermore, Id1 may confer resistance to treatment (both, radiotherapy and chemotherapy). Methods: We have studied, using monoclonal antibodies for immunohistochemistry, the Id1 and Id3 tumor epithelial expression in 17 patients with stage III-N2 non-small cell lung cancer (NSCLC) treated with definitive chemoradiotherapy. Results: Id1 expression is observed in 82.4% of the tumors, whereas Id3 expression is present in 41.2% of the samples. Interestingly, Id1 and Id3 expression are mutually correlated (R = 0.579, p = 0.015). In a subgroup analysis of patients with the most locally advanced disease (T4N2 stage), co-expression of Id1 and Id3 showed to be related with a worse overall survival (45 vs 6 months, p = 0.002). A trend towards significance for a worse progression free survival (30 vs 1 months, p = 0.219) and a lower response rate to the treatment (RR = 50% vs 87.5%, p = 0.07) were also observed. Conclusions: A correlation between Id1 and Id3 protein expression is observed. Id1 and Id3 co-expression seems associated with a poor clinical outcome in patients with locally advanced NSCLC treated with definitive chemoradiotherapy.

25 March 2015 in Cancers
Verified
Journal Article
Open access
PDF file
NSNele Van Der Steen
Nele Van Der Steen
Patrick PauwelsPatrick Pauwels
Patrick Pauwels
IGIgnacio Gil-Bazo
Ignacio Gil-Bazo
EÁEduardo Castañón Álvarez
Eduardo Castañón Álvarez
LRLuis E Raez
Luis E Raez
Christian RolfoChristian Rolfo
Christian Rolfo
In the last decade, the tyrosine kinase receptor cMET, together with its ligand hepatocyte growth factor (HGF), has become a target in non-small cell lung cancer (NSCLC). Signalization via cMET stimulates several oncological processes amongst which are cell motility, invasion and metastasis. It also confers resistance against several currently used targeted therapies, e.g., epidermal growth factor receptor (EGFR) inhibitors. In this review, we will discuss the basic structure of cMET and the most important signaling pathways. We will also look into aberrations in the signaling and the effects thereof in cancer growth, with the focus on NSCLC. Finally, we will discuss the role of cMET as resistance mechanism.

7 August 2015 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
EÁEduardo Castañón Álvarez
Eduardo Castañón Álvarez
Christian RolfoChristian Rolfo
Christian Rolfo
DVDavid Viñal
David Viñal
ILInés López
Inés López
JFJuan P Fusco
Juan P Fusco
IGIgnacio Gil-Bazo
Ignacio Gil-Bazo
Liver metastases appear in 20–30% of patients diagnosed with non-small cell lung cancer (NSCLC) and represent a poor prognosis feature of NSCLC and a possibly more treatment-resistant condition. Potential clinical outcome differences in NSCLC patients with liver metastases harboring molecular alterations in EGFR, KRAS and EML4-ALK genes are still to be determined. This study aims to evaluate the incidence of liver metastasis in a single population and look for potential correlations between EGFR mutations, liver infiltration and clinical outcomes. A total of 236 consecutive stage IV NSCLC patients treated at the Clínica Universidad de Navarra were analyzed. At onset, liver metastases were present in 16.9% of patients conferring them a shorter overall survival (OS) compared to those with different metastatic locations excluding liver infiltration (10 vs. 21 months; p = 0.001). Patients with EGFR wild-type tumors receiving standard chemotherapy and showing no liver involvement presented a superior median OS compared to those with liver metastases (23 vs. 13 months; p = 0.001). Conversely, patients with EGFR-mutated tumors treated with EGFR tyrosin-kinase inhibitors (TKI’s) presented no significant differences in OS regardless of liver involvement (median OS not reached vs. 25 months; p = 0.81). Overall, liver metastases at onset negatively impact OS of NSCLC patients. EGFR TKIs however, may reverse the effects of an initial negative prognosis of liver metastasis in first-line treatment of EGFR mutated NSCLC patients.

14 April 2014 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
EAEstefanía Arévalo
Estefanía Arévalo
EÁEduardo Castañón Álvarez
Eduardo Castañón Álvarez
ILInés López
Inés López
JSJosefa Salgado
Josefa Salgado
VCVíctor Collado
Víctor Collado
IGIgnacio Gil-Bazo
Ignacio Gil-Bazo
We studied whether thymidylate synthase (TS) genotype has an independent prognostic/predictive impact on a European population of advanced non-small cell lung cancer (NSCLC) patients receiving pemetrexed.

27 July 2021 in Cancers
Verified
Journal Article
Open access
PDF file
EAEdouard Auclin
Edouard Auclin
VPVuagnat Perrine
Vuagnat Perrine
CSCristina Smolenschi
Cristina Smolenschi
Julien TaiebJulien Taieb
Julien Taieb
JAJorge Adeva
Jorge Adeva
AHAntoine Hollebecque
Antoine Hollebecque
Background: MSI-H/dMMR is considered the first predictive marker of efficacy for immune checkpoint inhibitors (ICIs). However, around 39% of cases are refractory and additional biomarkers are needed. We explored the prognostic value of pretreatment LIPI in MSI-H/dMMR patients treated with ICIs, including identification of fast-progressors. Methods: A multicenter retrospective study of patients with metastatic MSI-H/dMMR tumors treated with ICIs between April 2014 and May 2019 was performed. LIPI was calculated based on dNLR > 3 and LDH > upper limit of normal. LIPI groups were good (zero factors), intermediate (one factor) and poor (two factors). The primary endpoint was overall survival (OS), including the fast-progressor rate (OS < 3 months). Results: A total of 151 patients were analyzed, mainly female (59%), with median age 64 years, performance status (PS) 0 (42%), and sporadic dMMR status (68%). ICIs were administered as first or second-line for 59%. The most frequent tumor types were gastrointestinal (66%) and gynecologic (22%). LIPI groups were good (47%), intermediate (43%), and poor (10%). The median follow-up was 32 months. One-year OS rates were 81.0%, 67.1%, and 21.4% for good, intermediate, and poor-risk groups (p < 0.0001). After adjustment for tumor site, metastatic sites and PS, LIPI remained independently associated with OS (HR, poor-LIPI: 3.50, 95%CI: 1.46–8.40, p = 0.02. Overall, the fast-progressor rate was 16.0%, and 35.7% with poor-LIPI vs. 7.5% in the good-LIPI group (p = 0.02). Conclusions: LIPI identifies dMMR patients who do not benefit from ICI treatment, particularly fast-progressors. LIPI should be included as a stratification factor for future trials.